The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PRIMROSE: A modular phase 1/2a study of AZD3470, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP deficient advanced solid tumors.
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); ArriVent Biopharma (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Scorpion Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst)
 
James Lau
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Maureen M. Hattersley
Employment - AstraZeneca
Stock and Other Ownership Interests - 7Department of Medical Oncology,
Research Funding - AstraZeneca
Patents, Royalties, Other Intellectual Property - AstraZeneca
 
Boaz E. Aronson
Employment - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Jane Peters
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Yee Soo-Hoo
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Research Funding - AstraZeneca
Patents, Royalties, Other Intellectual Property - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Aarti Sawant
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca; Pfizer
Travel, Accommodations, Expenses - AstraZeneca
 
Joanna Loizou
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Claire Smith
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca; Lilly
 
Emma Dean
Employment - AstraZeneca/MedImmune
Stock and Other Ownership Interests - AstraZeneca (I); AstraZeneca/MedImmune
Travel, Accommodations, Expenses - AstraZeneca
 
Sophie Postel-Vinay
Consulting or Advisory Role - Amgen (Inst); Daiichi Sankyo (Inst)
Research Funding - AstraZeneca (Inst); Roche/IMCore (Inst)
 
Benjamin J. Solomon
Honoraria - Amgen (Inst); AstraZeneca; Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech
Consulting or Advisory Role - Amgen; AstraZeneca (Inst); BeiGene; Bristol-Myers Squibb (Inst); GlaxoSmithKline; GlaxoSmithKline (Inst); Janssen (Inst); Lilly; Merck Sharp & Dohme; Pfizer (Inst); Roche/Genentech (Inst); Takeda
Research Funding - Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate